Zhou Zhou1, Francisca C Gushiken2, Doug Bolgiano1, Breia J Salsbery1, Niloufar Aghakasiri3, Naijie Jing4, Xiaoping Wu1, K Vinod Vijayan3, Rolando E Rumbaut5,6, Roberto Adachi7, Jose A Lopez1,8, Jing-Fei Dong1,9,8. 1. Puget Sound Blood Research Institute, Seattle, WA. 2. Department of Leukemia, the University of Texas M. D. Anderson Cancer Center, Houston, TX. 3. Section of Cardiovascular Sciences, Baylor College of Medicine, Houston, TX. 4. Section of Infectious Diseases, Baylor College of Medicine, Houston, TX. 5. Section of Critical Care and Pulmonary Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX. 6. Michael E. DeBakey VA Medical Center, Houston, TX. 7. Pulmonary Medicine, the University of Texas M. D. Anderson Cancer Center, Houston, TX. 8. Division of Hematology, Department of Medicine, University of Washington, School of Medicine, Seattle, WA. 9. General Hospital, Tianjin Medical University, Tianjin, China.
Abstract
BACKGROUND: Platelet hyperactivity induced by inflammation is a known risk factor for atherosclerosis and thrombosis, but its underlying mechanisms remain poorly understood. METHODS AND RESULTS: The signal transducer and activator of transcription 3 (STAT3) was activated in collagen-stimulated platelets. Activated STAT3 served as a protein scaffold to facilitate the catalytic interaction between the kinase Syk (spleen tyrosine kinase) and the substrate PLCγ2 to enhance collagen-induced calcium mobilization and platelet activation. The same interaction of STAT3 with Syk and PLCγ2 was detected in HEK293 cells transfected with cDNAs for Syk and PLCγ2 and stimulated with interleukin-6. Pharmacological inhibition of STAT3 blocked ≈50% of collagen- and a collagen-related peptide-induced but not thrombin receptor-activating peptide- or ADP-induced aggregation and ≈80% of thrombus formation of human platelets on a collagen matrix. This in vitro phenotype was reproduced in mice infused with STAT3 inhibitors and mice with platelet-specific STAT3 deficiency. By forming a complex with its soluble receptor, the proinflammatory cytokine interleukin-6 enhanced the collagen-induced STAT3 activation in human platelets. CONCLUSIONS: These data demonstrate a nontranscriptional activity of STAT3 that facilitates a crosstalk between proinflammatory cytokine and hemostasis/thrombosis signals in platelets. This crosstalk may be responsible for the platelet hyperactivity found in conditions of inflammation.
BACKGROUND:Platelet hyperactivity induced by inflammation is a known risk factor for atherosclerosis and thrombosis, but its underlying mechanisms remain poorly understood. METHODS AND RESULTS: The signal transducer and activator of transcription 3 (STAT3) was activated in collagen-stimulated platelets. Activated STAT3 served as a protein scaffold to facilitate the catalytic interaction between the kinase Syk (spleen tyrosine kinase) and the substrate PLCγ2 to enhance collagen-induced calcium mobilization and platelet activation. The same interaction of STAT3 with Syk and PLCγ2 was detected in HEK293 cells transfected with cDNAs for Syk and PLCγ2 and stimulated with interleukin-6. Pharmacological inhibition of STAT3 blocked ≈50% of collagen- and a collagen-related peptide-induced but not thrombin receptor-activating peptide- or ADP-induced aggregation and ≈80% of thrombus formation of human platelets on a collagen matrix. This in vitro phenotype was reproduced in mice infused with STAT3 inhibitors and mice with platelet-specific STAT3 deficiency. By forming a complex with its soluble receptor, the proinflammatory cytokine interleukin-6 enhanced the collagen-induced STAT3 activation in human platelets. CONCLUSIONS: These data demonstrate a nontranscriptional activity of STAT3 that facilitates a crosstalk between proinflammatory cytokine and hemostasis/thrombosis signals in platelets. This crosstalk may be responsible for the platelet hyperactivity found in conditions of inflammation.
Authors: K Takeda; K Noguchi; W Shi; T Tanaka; M Matsumoto; N Yoshida; T Kishimoto; S Akira Journal: Proc Natl Acad Sci U S A Date: 1997-04-15 Impact factor: 11.205
Authors: M Fontenay-Roupie; G Huret; J P Loza; R Adda; J Melle; J Maclouf; F Dreyfus; S Lévy-Toledano Journal: Thromb Haemost Date: 1998-01 Impact factor: 5.249
Authors: B S Gross; J R Lee; J L Clements; M Turner; V L Tybulewicz; P R Findell; G A Koretzky; S P Watson Journal: J Biol Chem Date: 1999-02-26 Impact factor: 5.157
Authors: Kunihiro Yamaoka; Pipsa Saharinen; Marko Pesu; Vance E T Holt; Olli Silvennoinen; John J O'Shea Journal: Genome Biol Date: 2004-11-30 Impact factor: 13.583
Authors: Sokha Nhek; Robert Clancy; Kristen A Lee; Nicole M Allen; Tessa J Barrett; Emanuela Marcantoni; Janet Nwaukoni; Sara Rasmussen; Maya Rubin; Jonathan D Newman; Jill P Buyon; Jeffrey S Berger Journal: Arterioscler Thromb Vasc Biol Date: 2017-02-02 Impact factor: 8.311
Authors: Elena Y Senchenkova; Janice Russell; Alper Yildirim; D Neil Granger; Felicity N E Gavins Journal: Hypertension Date: 2019-04 Impact factor: 10.190
Authors: J E Aslan; R A Rigg; M S Nowak; C P Loren; S M Baker-Groberg; J Pang; L L David; O J T McCarty Journal: J Thromb Haemost Date: 2015-08-29 Impact factor: 5.824